DCW LtdQ4 FY23
DCW Ltd Q4 FY23 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Price: ₹44.7P/E: 19.3Market Cap: ₹1.4K CrSector: Chemicals & Petrochemicals
Management growth scorecard
Revenue
Category 3
Margin
Category 3
Fundraise
N/A
Order
N/A
Capex
Yes
1 of 3 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
Category 3- CPVC and SIOP segments expected to grow with strong demand; CPVC demand is growing in double digits, especially in lower-tier cities and rural India.
- SIOP capacity utilization increased to ~80% with consistent growth in revenues and margins; plans to expand footprint in European markets.
- Specialty chemicals to maintain margins north of 35% with increasing volumes starting Quarter 2 and Quarter 3.
- Commodity chemicals like caustic soda prices seen as bottomed out; expected recovery as China's domestic demand improves.
- Overall volumes expected to increase with capacity additions in CPVC and SIOP, providing annualized EBITDA north of ₹220 crores post capex.
- Margins across segments expected to be maintained, with some quarter-to-quarter fluctuations due to price moves.
- Company targets a balanced portfolio between specialty and commodity chemicals for sustainable margin protection.
See what DCW Ltd management said on margin guidance — free account, 30 seconds.
Fundraise plans
- No immediate plans to repay debt; the company prefers to let debt reduce naturally through scheduled repayments (125 crores this year).
- Current gross debt stands at approximately 504 crores, with cash balances around 160 crores, resulting in net debt of about 340 crores.
- Management indicates the cost of borrowing has significantly reduced to sub-10% from around 17%.
- There is no explicit mention of new fundraising through debt or equity in the current period.
- Future decisions on debt repayment or new funding will depend on upcoming CAPEX requirements and growth projects, especially after completion of ongoing projects.
- The company is considering internal accruals to fund future CAPEX.
- No clear indication of equity fundraising or fresh debt issuance at present; the focus is on managing existing financial resources efficiently.
See what DCW Ltd management said on order book — free account, 30 seconds.
Capex plans
Yes- Current announced CAPEX is around ₹125 crores for doubling CPVC capacity and debottlenecking SIOP, with about ₹60 crores spent as of March 31 and 70% work done; some cost savings anticipated.
- Additional balance CAPEX of around ₹60 crores is required to complete announced projects.
- Routine CAPEX is about ₹30-40 crores.
- Total expected CAPEX spend including routine and announced projects for the year is around ₹100 crores.
- Future CAPEX includes making the Sahupuram facility chlorine neutral as part of ESG initiatives.
- Management is exploring renewable energy options like solar to reduce energy costs and carbon footprint.
- After completing current projects, the company plans to evaluate the next growth driver for FY25, including possible geographic de-risking and further expansion.
- Debt repayment decisions (₹125 crores repayment planned this year) will depend on CAPEX requirements and internal accruals.
Track DCW Ltd — get its next earnings analysis in your feed
Margin guidance
Category 3- Annualized profit from CPVC and SIOP capacity expected to be north of ₹200 crores post capacity coming online; current year will see partial benefit (Page 16).
- Specialty chemicals (SIOP and CPVC) projected EBITDA: ₹115 crores this year and over ₹220 crores next year post capex (Page 14).
- EBITDA margin for CPVC and SIOP expected to remain north of 35% on increased volumes (Page 6).
- Total EBITDA expected to exceed ₹200 crores with contributions from PVC (5-7% margin), caustic (3-4% margin), and soda ash segments (Page 15).
- EPS expected to grow with increased volumes and profitability in specialty chemicals and stabilization/recovery in commodity chemicals (implied across pages).
- Interest cost reduction and strong free cash flow to support profitability; no immediate debt repayment planned, allowing internal accruals to fund growth (Page 14 & 9).
- Long-term growth guided by capacity expansions, specialty chemical focus, and trading volumes (Pages 13, 11).
Order book
- The transcript does not explicitly mention the current or expected order book or pending orders.
- However, there is an indication of growth and positive demand in segments like CPVC and SIOP, with capacity expansions underway and expected volume ramp-up starting Q3 FY24.
- The company anticipates maintaining strong margins above 35% for specialty chemicals (SIOP and CPVC) with increased volumes.
- Discussions show confidence in sustaining or improving EBITDA supported by additional volumes despite price corrections.
- Management indicated stable operations with no mention of any backlog or pending orders causing concern.
- The company is focused on completing announced projects quickly to support the next phase of growth, implying active order flow and production ramp-up aligned with capacity expansions.
No direct order book numbers are provided in the transcript on page 17 or surrounding pages.
How does DCW Ltd rank vs peers in Chemicals & Petrochemicals?
Pro featureThisDCW Ltd
Rev 3Mar 3
How does DCW Ltd rank in Chemicals & Petrochemicals?
Compare DCW Ltd against every Chemicals & Petrochemicals company (Q4 FY23) on revenue, margins and earnings-call signals.
Continue your research
What DCW Ltd's management said in earlier quarters
Others in Chemicals & Petrochemicals this season
- Sudarshan Chemical Industries Ltd (Q1 FY27)
The net debt has already been reduced significantly from Rs.922 Crores at acquisition to Rs.531 Crores. Key concall takeaways from Sudarshan Chemical…
- Indo Borax & Ch. (Q1 FY27)
250-260 crores in FY27 with about 20% EBITDA margin, growing at 11-12% annually in absolute terms. Key concall takeaways from Indo Borax & Chemicals Ltd's Q1…
- SRF Ltd (Q1 FY27)
Chemicals business is guided for 15-20% growth in FY27, with a strong Q1 performance positioning the company to possibly hit the higher end of this range (Page…
- Deepak Fertilis. (Q1 FY27)
Long-term demand-supply balance looks stable with 6-7% market growth, supporting sustained revenues despite new capacity additions. Key concall takeaways from…